He used to serve as the Administrative Director of the Department of Nuclear Medicine and is now a rehired expert. He has extensive experience in the diagnosis and differential diagnosis of benign and malignant tumors using PET/CT, CT and other modalities. He has studied and exchanged in the departments of nuclear medicine in countries such as Germany and France.His expertise covers imaging examinations including PET/CT and CT for the diagnosis of systemic malignant tumors such as lung cancer and thymoma, identification of benign lesions such as pneumonia and pulmonary tuberculosis, accurate staging of systemic malignant tumors in early, middle and advanced stages, evaluation of postoperative recurrence, early and precise assessment of therapeutic efficacy after radiotherapy, chemotherapy and targeted drug therapy, as well as imaging diagnosis with SPECT/CT. In addition, he possesses unique methods and experience in the treatment of bone metastasis from malignant tumors.

PET/CT, CT, and other imaging examinations are used for the diagnosis of systemic malignant tumors such as lung cancer and thymoma, the assessment of benign conditions such as pneumonia and tuberculosis, as well as the precise staging of early, middle, and advanced systemic malignant tumors, the evaluation of postoperative recurrence, and the early and accurate assessment of therapeutic efficacy following radiotherapy, chemotherapy, and targeted drug therapy. Additionally, they include imaging d